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Summary: Cystic fibrosis has been characterized as a defect in the regulation of cyclic AMP-dependent trans-
epithelial chloride transport. The activation of cyclic AMP-dependent protein kinase A by cyclic AMP occurs
normally in cystic fibrosis cells, but they fail to transport chloride ions in response to protein kinase A stimulation.
Defective chloride secretion and abnormal electrolyte transport occurs in several organs including the lung, sweat
glands, intestine and pancreas. The present work was aimed at exploring whether the same or similar regulatory
systems are functional in platelets, and if they are altered or deficient in individuals with cystic fibrosis. Chloride
transport in platelets from normal subjects and from cystic fibrosis patients was measured by cell sizing techniques
where chloride permeability is the limiting factor. In platelets from healthy volunteers, the chloride channel blocker,
5-nitro-2-(3-phenylpropylamino) benzoic acid, inhibits the transport in a dose-dependent manner. The preservation
of chloride transport capability is shown to be dependent upon the presence of either Ca2"1" or two divalent cation
substitutes, Cd2+ or Cu2+. It is also shown that in normal subjects 0.1 μιηοΐ/ΐ prostaglandin El9 which elevates
cyclic AMP 6 times and abolishes platelet aggregation, significantly enhances the rate constant of the transport.
Furthermore, in five out of nine cystic fibrosis patients studied, platelet chloride transport did not respond to
stimulation by prostaglandin EI.
Introduction
Chloride transport in various cells is a topic of great NaCl medium in the presence of gramicidin react with
interest. In platelets, it has been studied in the context continuing swelling. In hypotonic Na2SO4 medium, on
of their volume-regulatory behaviour (1). When sub- the other hand, the initial swelling (osmotic equilibration
jected to hypotonic NaCl medium (200 mosmol/1) plate- — attributed to the inflow of water driven by the im-
lets respond with a rapid swelling phase of 30 seconds posed osmotic gradient) is followed by a modest shrink-
followed by a volume decrease with a partial return to- age. It was assumed that the platelet membrane is imper-
ward the original volume (1). The reduction in volume meable to SO^"", with shrinkage driven by the outward
in the second phase involves a loss of anions and potas- chloride gradient. When Na* is replaced by K"1" (or
sium ions. The addition of the ionophore gramicidin to Rb+) the volume decrease is abolished and the rapid
the medium induces a high permeability to both Na+ initial swelling phase is followed by a slower secondary
and K+, thus losses or gains of salts and the associated swelling (1). As expected, no secondary swelling was
changes in volume are limited by the conductive anion observed if Na+ was replaced by the impermeate cation
permeability and provide its measurement (2). It has N-methylglucamine. The rate of the secondary swelling
been shown (1) that platelets suspended in hypotonic in KC1 medium is substantially enhanced by the addition
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of gramicidin, suggesting that in swollen platelets potas-
sium permeability is the limiting factor of the rate of
swelling. When this limiting factor is removed by grami-
cidin, the swelling becomes limited by chloride perme-
ability. The permeabilities of two additional anions -
SCNT and NOf - behave like that of chloride, allow-
ing a rapid secondary swelling at comparative rates,
while citrate behaves like SOl". The present work ex-
tends the studies to the effect of divalent cations on the
platelet chloride permeability.
Cystic fibrosis is the most common congenital disease
among Caucasians. It is a disease of the secretory epi-
thelia, tissues that mediate the transport of chloride, ac-
companied by sodium and water, between the blood and
the lumen. The secretion requires activation of the secre-
tory pathway by hormones or neurotransmitters, utiliz-
ing cyclic AMP or Ca2+.
In recent years (1990-1992), the search for the basic
defect in cystic fibrosis has reached a decisive stage
since the identification of the responsible gene (3). It
has been suggested that the lOpS gene product entitled
cystic fibrosis transmembrane conductance regulator is
either a regulator protein directing a chloride channel to
the plasma membrane and conferring on it the ability to
be regulated by cyclic AMP (4), or that it is a regulated
chloride channel per se (5—7). Furthermore, the cystic
fibrosis transmembrane conductance regulator has been
purified to homogeneity and reconstituted into proteoli-
posomes in which it exhibited regulated chloride chan-
nel activity, providing evidence that the protein itself is
the channel (8).
Platelet conductive ion fluxes exhibit similar features to
those of epithelial cells (1), and are known to be respon-
sive to hormones such as epinephrine, which is impor-
tant in the regulation of fluid transport in the trachea
and in sweat glands. Thus, the aim of the present work
was to study chloride transport regulation in blood plate-




Gramicidin D, EGTA and prostaglandin EI were obtained from
Sigma Chemical Co. (St. Louis, MO); 5-nitro-2-(3-phenylpropyl-
amino) benzoic acid was a gift from Dr. B. Brauer from the Hebrew
University of Jerusalem.
Acid-citrate-dextrose solution was composed of 65 mmol/1 citric
acid, 11 mmol/1 glucose, and 85 mmol/1 trisodium citrate. The Tyr-
ode medium (modified), contained 137 mmol/1 NaCl, 1 mmol/1
KC1, 0.42 mmol/1 Na2HPO4> 0.5 mmol/1 MgCI2, 5.5 mmol/I glu-
cose and 20 mmol/1 HEPES, pH 7.35, adjusted to'290 mosmol/1.
Stock solution of gramicidin D (l mmol/1) was prepared in dimeth-
ylsulphoxide.
Subjects
Assays in control platelets were performed with blood samples
drawn randomly several times from ten healthy volunteers. Cystic
fibrosis patients were from the Pediatric Cystic Fibrosis Clinic of
the Soroka Medical Center, Ben-Gurion University Hospital in
Beer Sheva. For all the children the diagnosis of cystic fibrosis was
based on a sweat chloride concentration over 60 mmol/I and the
presence of either pancreatic insufficiency or chronic obstructive
pulmonary disease, or both. All the patients were under routine
standard therapy including daily chest physiotherapy (by parents),
high caloric diet with pancreatic enzymes and inhaled bronchodiia-
tors (p2-agonists). Antibiotics were given according to sputum cul-
ture results (only when exacerbation of respiratory symptoms oc-
curred). However, all children were without any acute symptoms
during the time of the study. All patients and/or their parents were
fully aware of the tests, so that the blood samples were taken only
after informed consent was obtained.
Mutations analysis
The mutations were studied by Dr. Bat-Sheva Kerem and cowork-
ers from the Hadassah Medical School, Hebrew University, Jerusa^
lem, as previously described (9).
Preparation of platelet suspension
Venous blood was obtained from subjects who had not taken any
medication during the preceding 10 days. The blood was collected
in plastic tubes and anticoagulated with acid-citrate-dextrose at a
volume ratio of blood : anticoagulant of 6 : 1. Platelet-rich plasma
was obtained by centrifugation at 120 g for 10 min and had a pH
of 6.5 ±0.1.
Gel-filtered platelets were obtained by passing 0.5-0.8 ml of
platelet-rich plasma through a Sepharose 2B column (5.5 X 0.76
cm), equilibrated with modified Tyrode medium. The platelets were
eluted with the same medium.
Platelet volume and chloride permeability
measurements
Volume measurements were conducted by electronic sizing using
a Coulter counter, model ZF with a Coulter channelyzer C1000.
Orifice diameter was 70 μηι. An aliquot of the platelet suspension
was diluted to a platelet count of 120 · 106/1. The mean cell volume
was calculated from the volume distribution curves using polysty-
rene latex beads for calibration. To determine the conductive anion
permeability as previously described (1), volume changes were
measured in the presence of the ionophore gramicidin to induce a
high permeability to Na+ and K+. As noted by Grinstein et al. (2),
under these conditions, losses or gains of salts and associated
changes in volume are limited by the conductive anion permeabil-
ity of the cell membrane. The volume changes, therefore, provide
a measure of anion permeability in general and of chloride perme-
ability in particular. For the measurements, platelets were sus-
pended in isotonic NaCl (Tyrone's modified medium) for 7.5 min-
utes in the presence of 0.4 μηιοΐ/ΐ gramicidin. On dilution with
water to 2/a of the original osmolarity, a very rapid, continuing
swelling is observed, indicating chloride permeability. The rate
constant of the permeability (relative volume change over time)
was calculated as described (1). For the experiments designed to
study the effect of divalent cations (figs, 2, 3 and 4) platelets were
suspended in isotonic medium containing a mixture of NaCl and
KC1 Tyrode solutions (2 + 1, by vol) and the suspension was di ·̂
luted with water as above. In figures 2 and 4, at the time points
indicated* individual aliquots were separated and treated with 0.4
μπιοΐ/ΐ gramicidin. The relative volume changes were measured by
electronic sizing.
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Other measurements
Cyclic AMP level in platelets was measured by a protein binding
assay according to oilman (10).
Platelet aggregation was assayed as previously described (11).
The final free Ca2"*" concentrations and the concentration of the
various divalent cations to be added to achieve a final free concen-
tration of 0.15 μπιοΐ/ΐ in the presence of 2mmol/l EGTA were
calculated by the software "Chelation 2", developed by Prof. D.
Chipman from Beer Sheva, according to the dissociation constants
of each of the cations with EGTA.
Results
In a previous paper (1), conditions were established for
the evaluation of the conductive anion permeability in
platelets. It is based on platelets suspended in isotonic
NaCl medium in the presence of the ionophore gramici-
din to induce a high permeability to cations. Upon in-
duction of hypotonicity, gain of chloride is associated
with volume increase, which is limited by the conduc-
tive chloride permeability. Thus, the extent of swelling
under these conditions apparently provides a measure-
ment of chloride permeability. Some characteristics of
the platelet conductive anion transport were described
(1).
If the system described indeed reflects conductive chlo-
ride permeability, then it is conceivable that an inhibitor
of chloride channels — 5-nitro-2-(3-phenylpropylamino)
benzoic acid — would inhibit the activity measured
comparable to results in other cell types (12, 13). Figure
1 depicts the inhibitory profile of 5-nitro-2-(3-phenyl-
propylamino) benzoic acid upon platelet chloride perme-
ability. The inhibition is detected at concentrations above
5 μπιοΐ/ΐ and reaches a plateau of 80% inhibition above
20 μιηοΐ/ΐ. Further characterization of the system is
now provided.
The involvement of divalent cations
In the previous study (1), it was shown that platelets,
suspended in an isotonic medium containing NaCl and
KC1 in a ratio of 2 : 1, upon induction of hypotonicity,
react by initial osmotic swelling and do not change their
volume for over one hour. Moreover, the maximal rates
of the secondary swelling, initiated by gramicidin added
at various times after the initial swelling, are remarkably
similar. Figure 2 shows the involvement of Ca2"1" in this
gramicidin-induced swelling. When 2 mmol/1 EGTA are
added to the platelet suspension, the half-life of the de-
cline of the chloride permeability is 30 ± 3 minutes
(mean of 11 experiments ± SE). However, the addition
of equimolar concentrations of both EGTA and Ca2+
(2 mmol/1) extends the capability of the process for at
least 50 minutes. Figure 3 depicts the dependence of the
permeability upon Ca2+ concentration. The concentra-
tion necessary to maintain half maximal activity (ci/2)
after 30 minutes in the hypotonic medium is 0.14
μιηοΐ/l. Is the effect of Ca2+ specific? This issue was
addressed by the comparison of the effect of seven diva-
lent cations of two different metal families: Mg, Ca, Sr
and Ba of the earth alkali metals and Mn, Cd and Cu of
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Fig. 1 Inhibition of the volume-induced chloride permeability by
5-nitro-2-(3-phenylpropylamino) benzoic acid.
Platelets (2 Χ 106) were suspended in 10 ml of isotonic Tyrode
medium (modified) in which Cl~~ is the predominant anion, supple-
mented with 0.4 μπιοΐ/l gramicidin. After 7.5 minutes the suspen-
sion was diluted with 5 ml of water to 200 mosmol/1 and the rela-
tive volume changes were measured by electronic sizing (a repre-
sentative Cl~ permeability sequence is depicted in fig. 5). 5-Nitro-
2-(3-phenylpropylamino) benoic acid at the indicated concentra-
tions was added 1 minute before the addition of the water.
Fig. 2 Effect of EGTA and Ca2+ on the extent of chloride perme-
ability with time.
Experimental conditions as in figure 1.
Gramicidin was omitted from the Tyrode medium. In parallel ex-
periments, the medium was supplemented by either 1 mmol/1 Ca2*
to serve as the control (D), 2 mmol/1 EGTA (Δ) or 2 mmol/1 EGTA
and 2 mmol/l Ca2+ (Φ). Gramicidin was added to the controls and
the tests at various time intervals after the induction of hypotonicity
(zero time), and chloride permeability, measured by cell swelling,
followed. The rate constants obtained with EGTA only or EGTA
and Ca2"1" at each time interval were compared with the correspond-
ing control designated as 100%.
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Fig. 3 The effect of extracellular free Ca2+ concentration on the
extent of chloride permeability.
The experimental design was as described in figure 2. EGTA and
Ca2"1" were added to the Tyrode medium to gain the final free Ca2+
concentrations as indicated. These were calculated by the software
"Chelaton 2" (Methods). Gramicidin was added 30 minutes after






Fig. 4 The effect of divalent cations on the extent of chloride
permeability with time.
Experimental conditions as in figure 3 with 2 mmol/1 EGTA and
appropriate concentrations of the cations to produce final free con-
centrations of 0.15 μηιοΐ/ΐ each. The calculation of the concentra-
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and at a final equal concentration of the free cation of
0.15 μτηοΐ/l, Ca2+, Cd2+ and Cu24" apparently show the
same "protective" effect while the other four fail to ful-
fill the need for the cation (fig. 4). This, of course, may
result from different (lower) affinities for Mn2+, Ba24",
Mg24" and Sr2*.
The impact of cyclic AMP
Since chloride channels in several cells are known to
be regulated by cyclic AMP levels (14-16), and since
prostaglandin E] is known to elevate cyclic AMP con-
centrations (17), the effect of prostaglandin EI on plate-
let swelling limited by chloride permeability was
studied. Figure 5 depicts an accelerated chloride perme-
ability in the presence of 0.1 μιηοΐ/ΐ prostaglandin EI.
Table 1 summarizes the results of ten similar experi-
ments showing a statistically significant 44% enhance-
ment of the apparent platelet chloride permeability
caused by prostaglandin E}. Is the effect of prostaglan-
din E! mediated by cyclic AMP? Two lines of evidence
suggest a positive answer. First, table 2 demonstrates
that under the conditions of the experiments described
in figure 5 and table 1, cyclic AMP concentration is
indeed elevated six fold by prostaglandin E,. Secondly,
ADP-induced platelet aggregation, known to be inhib-
ited by elevated cyclic AMP concentrations, was totally
abolished by as little as 0.02 μπιοΐ/ΐ prostaglandin E!
(data not shown).
Of particular interest is whether the system described
has any relevance to the expression of cystic fibrosis. In
view of the fact that it has been shown that the defect hi
cystic fibrosis patients is not the activity of the chloride
channel but rather its response to control mechanisms
such as an increase by cyclic AMP-dependent protein
kinase (15, 18), the response of platelet chloride trans-
port to prostaglandin E! in cystic fibrosis patients was
evaluated (tab. 3). Nine patients were probed. Their rate
constants of chloride permeability did not differ from
those of healthy volunteers. However, five of them did
not respond to prostaglandin Ej (as compared to a mini-
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Fig. 5 Effect of prostaglandin E, on chloride permeability in con-
trol platelets. Experimental conditions - as described for figure 1.
Prostaglandin E! 0.1 μιηοΐ/ΐ (solid circles) or its solvent - 1 ml
ethanol (open circles) were added at the time-of dilution. Represen-
tative^ ten experiments.
Temperature was 25 °C.
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subjects studied, summarized in tab. 1), but four did re-
spond normally to the prostaglandin.





Prostaglandin E], 0.1 μηιοΐ/ΐ
0.109 ± 0.008
0.157 ±0.011
The experimental conditions were as in figures 1 and 5.
Results are means of ten experiments ± S. E.
The stimulatory effect of prostaglandin E, is statistically significant
according to the Student's t test, p < 0.01. Neither of the individ-
uals studied responded by less than 15% augmentation.
Tab. 2
tration




Prostaglandin EI, 0.1 μηιοΐ/ΐ
2.8
17.0
Platelet-rich plasma was incubated with either ethanol (1 ml/1) or
prostaglandin EI (0.1 μπιοΐ/ΐ) for one minute, followed by centrifu-
gation and aspiration of the supernatant.
Cyclic AMP in the pellet was extracted by boiling for 5 min in 50
mmol/1 acetate buffer pH 4.O.
The results are means of duplicates.
Tab. 3 Response of volume-induced chloride permeability of cys-


























































The experimental conditions are as in figure 1.
Each patient was assayed versus an age- and sex-matched healthy
volunteer.
At least four assays were carried out from a given patient's blood
sample.
Two of the patients were assayed under two different occasions
with the same results.
* The values express the stimulation of the rate constant caused by
0.1 μιποΐ/ΐ prostaglandin Ej as compared with the vehicle (aqueous
ethanol, volume fraction 0.7)
** Not available.
Discussion
Conductive platelet anion permeability, mainly chloride
permeability, is relatively low in isotonic medium and
increases substantially on hypotonic swelling (1). This
fact was used in the present work to study the control
of this conductive feature in healthy people as well as
in cystic fibrosis patients. To further support the inter-
pretation that the assay previously developed (1) does
indeed measure chloride transport, inhibition by a chlo-
ride channel blocker, 5-iutro-2-(3-phenylpropylamino)
benzoic acid (12, 13), is documented, which adds to the
previously observed inhibition by oligomycin C (1),
shown to inhibit chloride pathways in lymphocytes (19).
However, the results of Haws et al. (20) of "little or no
inhibition" of cystic fibrosis transmembrane conduct-
ance regulator channels in immortalized human airway
cells by 100 μπιοΐ/ΐ 5-nitro-2-(3-phenylpropylamino)
benzoic acid prevent us from drawing an unequivocal
conclusion.
The dependence of the chloride permeability upon spe-
cific divalent cations indicates that there are at least two
factors which affect chloride transport in platelets; one
is catabolic — associated with cyclic AMP, and the other
is concerned with cations. Another possibility, as shown
for epithelial cells (21, 22) and epithelial apical mem-
brane (23), is that Ca2+ and cyclic AMP activate dif-
ferent chloride channels (23). Other options - such as
the change in Ca2H" concentrations resulting in altered
cytoskeleton and subsequent swelling — are still open.
Apical chloride channels are opened and chloride secre-
tion is stimulated by a variety of hormones and neuro-
transmitters that increase intracellular levels of cyclic
AMP (24, 25). The same regulatory pattern is now prin-
cipally demonstrated in platelets. Prostaglandin EI en-
hances cell swelling limited by chloride permeability, an
effect that correlates with the elevation of cyclic AMP
levels and with the inhibition of platelet aggregation
well known to occur upon increased cyclic AMP con-
centration (17). Nevertheless, it cannot be ruled out that
cyclic AMP alters platelet cytoskeleton, changes intra-
cellular Ca2+ concentrations or activates transporters,
resulting in a relative volume change.
In cystic fibrosis patients, the main molecular defect has
been identified as chloride impermeability in various ep-
ithelia (26—30). In fact, hormonal secretagogues do
stimulate cyclic AMP accumulation appropriately, but
the chloride channels fail to open (26, 31). To study
the pathophysiology of the disease at the biochemical-
physiological regulatory level in platelets, the effect of
prostaglandin Et on platelet chloride conductive perme-
ability in cystic fibrosis patients was probed. The well
known heterogeneity in the clinical presentation of cys-
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tic fibrosis, such as the involvement or absence of pan-
creatic insufficiency (32), and tike variation in the sever-
ity of the disease in the whole community (33) have
been partially attributed to different mutations at the
cystic fibrosis locus. Studies of the correlation of cystic
fibrosis mutations with pancreatic function, meconium
ileus, liver involvement, lung disease and gender have
been reported and reviewed (34, 35). Relevant exam-
ples are:
(a) remarkable correlation between ΔΡ508 homozygos-
ity (AF508/AF508) and pancreatic insufficiency ("se-
vere" mutation) versus a genotype of AF508/non-AF508
or non-AF508/non-AF508 that have a mutant cystic fi-
brosis product that confers a sufficient phenotype (36);
(b) a severe disease, reflected by pancreatic insuffi-
ciency, high incidence of meconium ileus, early age at
diagnosis, poor nutritional status and variable pulmonary
function, is associated with homozygosity for the
W1282X mutation and the heterozygosity for the AF508
and W1282X mutations (9). The variability is intrigu-
ingly reflected in the patients studied by us as well. Of
the nine tested, five patients lacked the regulatory re-
sponse to prostaglandin E! stimulation, whereas the
other four were responsive. Although the number of pa-
tients is limited, it is notable that in agreement with the
examples described above, neither of the four respond-
ing patients exhibits the "severe" mutations, while three
out of the five non-responders possess the severe mut-
ations (F. E., P. A. and H. B.) while the other two carry
the rare mutation 3849 + lOkbC —* T which is not yet
well characterized. Along with the fact that the chloride
channel response to cyclic AMP-dependent protein ki-
nase is defected in cystic fibrosis patients rather than the
activity itself, there is good evidence that some mutant
cystic fibrosis transmembrane conductance regulators
are defectively processed (37) and that the very activity
of the chloride channel is altered (38). Such mutations
have been implicated to be associated with the mild-
disease-form. Thus, it may also be suggested that the
four responding patients in the present study belong to
this group of mutations. It is interesting to point out that
the non-responsive patients in the present study were all
above nine years old, while the responsive ones were
aged three years or less. Such a phehomenon could theo-
retically be understood if cystic fibrosis were an ac-
quired disease but not a congenital one. Yet, the majority
of the patients are diagnosed by the time of adolescence.
This fact may suggest that although hereditary, some of
the molecular manifestations of the disease are ex-
pressed at a later stage of life. It might be that at an early
stage some of the components of the chloride transport
complex are still capable of leaking adequately from the
endosomal membranes to the functional sites in the
plasma membrane. At later stages of life they may be-
come arrested for numerous reasons, as yet unclear.
Such a possibility adds interest to the study of the sys-
tem, but it does not allow the use of the assay of prosta-
glandin E! enhancement of platelet chloride conductive
permeability as a reliable diagnostic tool for cystic fibro-
sis. It could, however, be used as a tool to follow the
development of the disease. The main advantage of the
platelet system is that it serves as an easily available,
simple assay system to further study characteristics of
the chloride transport system in health and disease.
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